Tradjenta

ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
ADA
diabetes
Tradjenta
Flag link:
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
glimepiride
linagliptin
Tradjenta
type 2 diabetes
clinical trials
Flag link:
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Tradjenta
diabetes
Flag link:
Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
clinical trials
diabetes
Tradjenta
Flag link:
Show me the money: Which drugs made the top 10 list on upfront deals?
Show me the money: Which drugs made the top 10 list on upfront deals?
Fierce Biotech
biotech
GED-0301
Celgene
Nogra Pharma
AbbVie
Reata
Bardoxolone
Abbott Labs
Tradjenta
Eli Lilly
Boehringer Ingelheim
FG-4592
AstraZeneca
FibroGen
Pfizer
Bristol-Myers Squibb
Eliquis
Moderna
Forma Therapeutics
dimebon
Medivation
Jakafi
Novartis
Incyte
Flag link:
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
Yahoo/PR Newswire
Tradjenta
diabetes
type 2 diabetes
Boehringer Ingelheim
Eli Lilly
Flag link:
Diabetes Drugs Under Scrutiny As FDA Considers Another Study
Diabetes Drugs Under Scrutiny As FDA Considers Another Study
Pharmalot
FDA
diabetes
Merck
Januvia
Onglyza
Bristol-Myers Squibb
Byetta
AstraZeneca
Eli Lilly
Novo Nordisk
Victoza
Tradjenta
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim and Lilly initiate MARLINA clinical trial to evaluate use of Tradjenta® (linagliptin) tablets in patients with type 2 diabetes and albuminuria
Boehringer Ingelheim and Lilly initiate MARLINA clinical trial to evaluate use of Tradjenta® (linagliptin) tablets in patients with type 2 diabetes and albuminuria
Yahoo
Eli Lilly
Boehringer Ingelheim
Tradjenta
diabetes
albuminuria
Flag link:
Drugmaker Eli Lilly starts sales this week for combination diabetes treatment Jentadueto
Drugmaker Eli Lilly starts sales this week for combination diabetes treatment Jentadueto
Yahoo/AP
Eli Lilly
diabetes
Jentadueto
metformin
Tradjenta
Flag link:
Boehringer Ingelheim and Lilly's New Type 2 Diabetes Treatment Tradjenta (Linagliptin) Tablets for Adults Now Available in U.S. Pharmacies
Boehringer Ingelheim and Lilly's New Type 2 Diabetes Treatment Tradjenta (Linagliptin) Tablets for Adults Now Available in U.S. Pharmacies
Pharma Live
Eli Lilly
Boehringer Ingelheim
type 2 diabetes
Tradjenta
Flag link: